The Bipolar Big Three: LAIs, Atypical Antipsychotics And Symptom Specific Drugs

Room For Growth Beyond Generics

14 Feb 2022

• By Ayisha Sharma

Despite the highly genericized nature of the bipolar disorder market, firms have innovated with long-acting injectables, improved atypical antipsychotics and drugs targeting specific symptoms.

Two-headed silhouette, mental health disorder concept. — BD Is Influenced By Social, Environmental And Genetic Factors • Source: Alamy

The bipolar disorder (BD) market is dominated by generics but a recent Datamonitor Healthcare report highlighted that atypical long-acting injectables (LAIs) show strong growth potential and there are still gaps in the treatment paradigm. Scrip spoke with some of the leading R&D firms about trends and challenges in the space.

“Doctors often assume that patients don’t want injectable treatments but this is not necessarily the case,” said Oliver Howes, head...